{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:00:51Z","timestamp":1791259251717,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002301","name":"Eesti Teadusagentuur","doi-asserted-by":"publisher","award":["PRG230 and PRG1788"],"award-info":[{"award-number":["PRG230 and PRG1788"]}],"id":[{"id":"10.13039\/501100002301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002301","name":"Eesti Teadusagentuur","doi-asserted-by":"publisher","award":["PRG230 and PRG1788"],"award-info":[{"award-number":["PRG230 and PRG1788"]}],"id":[{"id":"10.13039\/501100002301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002301","name":"Eesti Teadusagentuur","doi-asserted-by":"publisher","award":["PRG230 and PRG1788"],"award-info":[{"award-number":["PRG230 and PRG1788"]}],"id":[{"id":"10.13039\/501100002301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002301","name":"Eesti Teadusagentuur","doi-asserted-by":"publisher","award":["PRG230 and PRG1788"],"award-info":[{"award-number":["PRG230 and PRG1788"]}],"id":[{"id":"10.13039\/501100002301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002301","name":"Eesti Teadusagentuur","doi-asserted-by":"publisher","award":["PRG230 and PRG1788"],"award-info":[{"award-number":["PRG230 and PRG1788"]}],"id":[{"id":"10.13039\/501100002301","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EuronanomedIII projects","award":["ECM-CART"],"award-info":[{"award-number":["ECM-CART"]}]},{"name":"EuronanomedIII projects","award":["ECM-CART"],"award-info":[{"award-number":["ECM-CART"]}]},{"name":"EuronanomedIII projects","award":["ECM-CART"],"award-info":[{"award-number":["ECM-CART"]}]},{"name":"EuronanomedIII projects","award":["ECM-CART"],"award-info":[{"award-number":["ECM-CART"]}]},{"name":"EuronanomedIII projects","award":["ECM-CART"],"award-info":[{"award-number":["ECM-CART"]}]},{"name":"iNanoGun and TRANSCAN3 project","award":["ReachGLIO"],"award-info":[{"award-number":["ReachGLIO"]}]},{"name":"iNanoGun and TRANSCAN3 project","award":["ReachGLIO"],"award-info":[{"award-number":["ReachGLIO"]}]},{"name":"iNanoGun and TRANSCAN3 project","award":["ReachGLIO"],"award-info":[{"award-number":["ReachGLIO"]}]},{"name":"iNanoGun and TRANSCAN3 project","award":["ReachGLIO"],"award-info":[{"award-number":["ReachGLIO"]}]},{"name":"iNanoGun and TRANSCAN3 project","award":["ReachGLIO"],"award-info":[{"award-number":["ReachGLIO"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-11299-x","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T12:54:03Z","timestamp":1754916843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting oncofetal fibronectin and neuropilin-1 in solid tumors with PL2 peptide"],"prefix":"10.1038","volume":"15","author":[{"given":"Prakash","family":"Lingasamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Tobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaarel","family":"Kurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Tammik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tambet","family":"Teesalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"11299_CR1","doi-asserted-by":"crossref","unstructured":"Guelfi, S., Hodivala-Dilke, K. & Bergers, G. Targeting the tumour vasculature: from vessel destruction to promotion. Nat. Rev. Cancer 24, 1456 (2024).","DOI":"10.1038\/s41568-024-00736-0"},{"key":"11299_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/HP.S133231","volume":"5","author":"J Forster","year":"2017","unstructured":"Forster, J., Harriss-Phillips, W., Douglass, M. & Bezak, E. A review of the development of tumor vasculature and its effects on the tumor microenvironment. Hypoxia 5, 21\u201332 (2017).","journal-title":"Hypoxia"},{"key":"11299_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1083\/jcb.200910104","volume":"188","author":"E Ruoslahti","year":"2010","unstructured":"Ruoslahti, E., Bhatia, S. N. & Sailor, M. J. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 188, 759\u2013768 (2010).","journal-title":"J. Cell Biol."},{"key":"11299_CR4","unstructured":"Lingasamy, P. Development of Multitargeted Tumor Penetrating Peptides (University of Tartu, 2020). http:\/\/hdl.handle.net\/10062\/70738."},{"key":"11299_CR5","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-22-1532","volume":"83","author":"N Jailkhani","year":"2023","unstructured":"Jailkhani, N. et al. Proteomic profiling of extracellular matrix components from patient metastases identifies consistently elevated proteins for developing nanobodies that target primary tumors and metastases. Cancer Res. 83, 2052 (2023).","journal-title":"Cancer Res."},{"key":"11299_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-030-58174-9_2","volume":"1295","author":"P Lingasamy","year":"2021","unstructured":"Lingasamy, P. & Teesalu, T. Homing peptides for Cancer therapy. Adv. Exp. Med. Biol. 1295, 29\u201348 (2021).","journal-title":"Adv. Exp. Med. Biol."},{"key":"11299_CR7","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.3390\/pharmaceutics13121998","volume":"13","author":"P Lingasamy","year":"2021","unstructured":"Lingasamy, P. et al. PL1 peptide engages acidic surfaces on Tumor-Associated fibronectin and Tenascin isoforms to trigger cellular uptake. Pharmaceutics 13, 1998 (2021).","journal-title":"Pharmaceutics"},{"key":"11299_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ctdb.2018.02.002","volume":"130","author":"JM Muncie","year":"2018","unstructured":"Muncie, J. M. & Weaver, V. M. The physical and biochemical properties of the extracellular matrix regulate cell fate. Curr. Top. Dev. Biol. 130, 1 (2018).","journal-title":"Curr. Top. Dev. Biol."},{"key":"11299_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.matbio.2022.05.003","volume":"111","author":"Z Rekad","year":"2022","unstructured":"Rekad, Z., Izzi, V., Lamba, R., Ciais, D. & Van Obberghen-Schilling, E. The alternative matrisome: alternative splicing of ECM proteins in development, homeostasis and tumor progression. Matrix Biol. 111, 26\u201352 (2022).","journal-title":"Matrix Biol."},{"key":"11299_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10456-005-9017-6","volume":"8","author":"ZA Khan","year":"2005","unstructured":"Khan, Z. A. et al. EDB fibronectin and angiogenesis - a novel mechanistic pathway. Angiogenesis 8, 183\u2013196 (2005).","journal-title":"Angiogenesis"},{"key":"11299_CR11","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1002\/j.1460-2075.1987.tb02509.x","volume":"6","author":"L Zardi","year":"1987","unstructured":"Zardi, L. et al. Transformed human cells produce a new fibronectin isoform by Preferential alternative splicing of a previously unobserved exon. EMBO J. 6, 2337\u20132342 (1987).","journal-title":"EMBO J."},{"key":"11299_CR12","doi-asserted-by":"publisher","first-page":"941","DOI":"10.7150\/thno.44948","volume":"11","author":"PE Saw","year":"2021","unstructured":"Saw, P. E. et al. Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma. Theranostics 11, 941\u2013957 (2021).","journal-title":"Theranostics"},{"key":"11299_CR13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/ijc.2910590507","volume":"59","author":"P Castellani","year":"1994","unstructured":"Castellani, P. et al. The fibronectin isoform containing the ed-b oncofetal domain: a marker of angiogenesis. Int. J. Cancer. 59, 612\u2013618 (1994).","journal-title":"Int. J. Cancer"},{"key":"11299_CR14","unstructured":"Teesalu, T. & Lingasamy, P. Bi-Specific extracellular matrix binding peptides and methods of use thereof. PCT Patent No WO 2020161602A1  (2020)."},{"key":"11299_CR15","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1002\/1878-0261.12705","volume":"14","author":"RIY Lieverse","year":"2020","unstructured":"Lieverse, R. I. Y. et al. Human fibronectin extra domain B as a biomarker for targeted therapy in cancer. Mol. Oncol. 14, 1555\u20131568 (2020).","journal-title":"Mol. Oncol."},{"key":"11299_CR16","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.2217\/fon-2019-0433","volume":"15","author":"JT Miura","year":"2019","unstructured":"Miura, J. T. & Zager, J. S. Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB\/C melanoma. Future Oncol. 15, 3665\u20133674 (2019).","journal-title":"Future Oncol."},{"key":"11299_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/JDV.20163","author":"L Flatz","year":"2024","unstructured":"Flatz, L. et al. Intratumoral administration of Daromun in non-melanoma skin cancer: preliminary results from a phase 2 non-randomized controlled trial. J. Eur. Acad. Dermatol. Venereol. https:\/\/doi.org\/10.1111\/JDV.20163 (2024).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"11299_CR18","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00262-015-1704-6","volume":"64","author":"R Danielli","year":"2015","unstructured":"Danielli, R. et al. Intralesional administration of L19-IL2\/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol. Immunother. 64, 999\u20131009 (2015).","journal-title":"Cancer Immunol. Immunother"},{"key":"11299_CR19","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.4155\/fmc.12.94","volume":"4","author":"F Albericio","year":"2012","unstructured":"Albericio, F. & Kruger, H. G. Therapeutic peptides. Future Med. Chem. 4, 1527\u20131531 (2012).","journal-title":"Future Med. Chem."},{"key":"11299_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2174\/1871520617666170419143459","volume":"18","author":"N Zhao","year":"2017","unstructured":"Zhao, N., Qin, Y., Liu, H. & Cheng, Z. Tumor-Targeting peptides: ligands for molecular imaging and therapy. Anticancer Agents Med. Chem. 18, 74\u201386 (2017).","journal-title":"Anticancer Agents Med. Chem."},{"key":"11299_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","volume":"20","author":"K Fosgerau","year":"2015","unstructured":"Fosgerau, K. & Hoffmann, T. Peptide therapeutics: current status and future directions. Drug Discov Today. 20, 122\u2013128 (2015).","journal-title":"Drug Discov Today"},{"key":"11299_CR22","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1021\/acs.bioconjchem.5b00178","volume":"26","author":"Z Han","year":"2015","unstructured":"Han, Z. et al. EDB fibronectin specific peptide for prostate Cancer targeting. Bioconjug. Chem. 26, 830\u2013838 (2015).","journal-title":"Bioconjug. Chem."},{"key":"11299_CR23","doi-asserted-by":"publisher","first-page":"119373","DOI":"10.1016\/j.biomaterials.2019.119373","volume":"219","author":"P Lingasamy","year":"2019","unstructured":"Lingasamy, P. et al. Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery. Biomaterials 219, 119373 (2019).","journal-title":"Biomaterials"},{"key":"11299_CR24","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/jjco\/hyp074","volume":"39","author":"A Nagamitsu","year":"2009","unstructured":"Nagamitsu, A., Greish, K. & Maeda, H. Elevating blood pressure as a strategy to increase Tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn J. Clin. Oncol. 39, 756\u2013766 (2009).","journal-title":"Jpn J. Clin. Oncol."},{"key":"11299_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3390\/jpm13030389","volume":"13","author":"MA Subhan","year":"2023","unstructured":"Subhan, M. A., Parveen, F., Filipczak, N., Yalamarty, S. S. K. & Torchilin, V. P. Approaches to improve EPR-Based drug delivery for Cancer therapy and diagnosis. J. Personalized Med. 2023. 13, 389 (2023).","journal-title":"J. Personalized Med. 2023"},{"key":"11299_CR26","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1038\/s41598-020-62760-y","volume":"10","author":"P Lingasamy","year":"2020","unstructured":"Lingasamy, P. et al. Tumor-penetrating peptide for systemic targeting of Tenascin-C. Sci. Rep. 10, 5809 (2020).","journal-title":"Sci. Rep."},{"key":"11299_CR27","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1007\/s13346-024-01670-2","volume":"14","author":"A Tobi","year":"2024","unstructured":"Tobi, A. et al. Protease-activated CendR peptides targeting tenascin-C: mitigating off-target tissue accumulation. Drug Deliv Transl Res. 14, 2945\u20132961 (2024).","journal-title":"Drug Deliv Transl Res."},{"key":"11299_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2174\/1568009620666201001112749","volume":"21","author":"P Lingasamy","year":"2021","unstructured":"Lingasamy, P., Laarmann, A. H. & Teesalu, T. Tumor penetrating Peptide-Functionalized Tenascin-C antibody for glioblastoma targeting. Curr. Cancer Drug Targets. 21, 70\u201379 (2021).","journal-title":"Curr. Cancer Drug Targets"},{"key":"11299_CR29","doi-asserted-by":"publisher","first-page":"16157","DOI":"10.1073\/pnas.0908201106","volume":"106","author":"T Teesalu","year":"2009","unstructured":"Teesalu, T., Sugahara, K. N., Kotamraju, V. R. & Ruoslahti, E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc. Natl. Acad. Sci. U S A. 106, 16157\u201316162 (2009).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"11299_CR30","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ccr.2009.10.013","volume":"16","author":"KN Sugahara","year":"2009","unstructured":"Sugahara, K. N. et al. Tissue-Penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell. 16, 510\u2013520 (2009).","journal-title":"Cancer Cell."},{"key":"11299_CR31","doi-asserted-by":"publisher","first-page":"17578","DOI":"10.1074\/jbc.M111.303131","volume":"287","author":"A Schiefner","year":"2012","unstructured":"Schiefner, A., Gebauer, M. & Skerra, A. Extra-domain B in oncofetal fibronectin structurally promotes fibrillar head-to-tail dimerization of extracellular matrix protein. J. Biol. Chem. 287, 17578\u201317588 (2012).","journal-title":"J. Biol. Chem."},{"key":"11299_CR32","doi-asserted-by":"publisher","first-page":"31955","DOI":"10.18632\/oncotarget.7454","volume":"7","author":"S Bougnaud","year":"2016","unstructured":"Bougnaud, S. et al. Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma. Oncotarget 7, 31955\u201331971 (2016).","journal-title":"Oncotarget"},{"key":"11299_CR33","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00401-013-1101-1","volume":"125","author":"KM Talasila","year":"2013","unstructured":"Talasila, K. M. et al. EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathol. 125, 683\u2013698 (2013).","journal-title":"Acta Neuropathol."},{"key":"11299_CR34","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1073\/pnas.1014480108","volume":"108","author":"O Keunen","year":"2011","unstructured":"Keunen, O. et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl. Acad. Sci. U S A. 108, 3749\u20133754 (2011).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"11299_CR35","doi-asserted-by":"publisher","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 8, e1000412 (2010).","journal-title":"PLoS Biol."},{"key":"11299_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/B978-0-12-396962-0.00002-1","volume":"503","author":"T Teesalu","year":"2012","unstructured":"Teesalu, T., Sugahara, K. N. & Ruoslahti, E. Mapping of vascular ZIP codes by phage display. Methods Enzymol. 503, 35\u201356 (2012).","journal-title":"Methods Enzymol."},{"key":"11299_CR37","doi-asserted-by":"publisher","first-page":"101042831770162","DOI":"10.1177\/1010428317701628","volume":"39","author":"H Ikemoto","year":"2017","unstructured":"Ikemoto, H. et al. Hyaluronan-binding peptide for targeting peritoneal carcinomatosis. Tumor Biol. 39, 1010428317701628 (2017).","journal-title":"Tumor Biol."},{"key":"11299_CR38","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/978-1-0716-1752-6_25","volume":"2383","author":"K P\u00f5\u0161nograjeva","year":"2022","unstructured":"P\u00f5\u0161nograjeva, K., Pleiko, K., Haugas, M. & Teesalu, T. New tools for streamlined in vivo homing peptide identification. Methods Mol. Biol. 2383, 385\u2013412 (2022).","journal-title":"Methods Mol. Biol."},{"key":"11299_CR39","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1002\/adma.200800004","volume":"20","author":"JH Park","year":"2008","unstructured":"Park, J. H. et al. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv. Mater. 20, 1630\u20131635 (2008).","journal-title":"Adv. Mater."},{"key":"11299_CR40","doi-asserted-by":"publisher","first-page":"9096","DOI":"10.1039\/C5NR07928D","volume":"8","author":"AMA Willmore","year":"2016","unstructured":"Willmore, A. M. A. et al. Targeted silver nanoparticles for ratiometric cell phenotyping. Nanoscale 8, 9096\u20139101 (2016).","journal-title":"Nanoscale"},{"key":"11299_CR41","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jconrel.2019.06.018","volume":"308","author":"P S\u00e4\u00e4lik","year":"2019","unstructured":"S\u00e4\u00e4lik, P. et al. Peptide-guided nanoparticles for glioblastoma targeting. J. Controlled Release. 308, 109\u2013118 (2019).","journal-title":"J. Controlled Release"},{"key":"11299_CR42","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. Declaration of helsinki: ethical principles for medical research involving human subjects. JAMA 310, 2191\u20132194 (2013).","journal-title":"JAMA"},{"key":"11299_CR43","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/0261192920911339","volume":"48","author":"M Balls","year":"2020","unstructured":"Balls, M. It\u2019s time to reconsider the principles of humane experimental technique. Altern. Lab. Anim. 48, 40\u201346 (2020).","journal-title":"Altern. Lab. Anim."},{"key":"11299_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/0023677217724823","volume":"52","author":"AJ Smith","year":"2018","unstructured":"Smith, A. J., Clutton, R. E., Lilley, E., Hansen, K. E. A. & Brattelid, T. PREPARE: guidelines for planning animal research and testing. Lab. Anim. 52, 135\u2013141 (2018).","journal-title":"Lab. Anim."},{"key":"11299_CR45","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nmat3982","volume":"13","author":"GB Braun","year":"2014","unstructured":"Braun, G. B. et al. Etchable plasmonic nanoparticle probes to image and quantify cellular internalization. Nat. Mater. 13, 904\u2013911 (2014).","journal-title":"Nat. Mater."},{"key":"11299_CR46","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1002\/adma.201200454","volume":"24","author":"E Ruoslahti","year":"2012","unstructured":"Ruoslahti, E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv. Mater. 24, 3747\u20133756 (2012).","journal-title":"Adv. Mater."},{"key":"11299_CR47","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","volume":"1","author":"S Wilhelm","year":"2016","unstructured":"Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).","journal-title":"Nat. Rev. Mater."},{"key":"11299_CR48","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/smll.200801789","volume":"5","author":"JH Park","year":"2009","unstructured":"Park, J. H. et al. Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small 5, 694\u2013700 (2009).","journal-title":"Small"},{"key":"11299_CR49","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1182\/blood-2010-03-274258","volume":"116","author":"L Agemy","year":"2010","unstructured":"Agemy, L. et al. Nanoparticle-induced vascular Blockade in human prostate cancer. Blood 116, 2847\u20132856 (2010).","journal-title":"Blood"},{"key":"11299_CR50","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1021\/acs.nanolett.6b03815","volume":"17","author":"S Sharma","year":"2017","unstructured":"Sharma, S. et al. Tumor-Penetrating nanosystem strongly suppresses breast tumor growth. Nano Lett. 17, 1356\u20131364 (2017).","journal-title":"Nano Lett."},{"key":"11299_CR51","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.ygyno.2007.02.005","volume":"105","author":"T Baba","year":"2007","unstructured":"Baba, T. et al. Neuropilin-1 promotes unlimited growth of ovarian cancer by evading contact Inhibition. Gynecol. Oncol. 105, 703\u2013711 (2007).","journal-title":"Gynecol. Oncol."},{"key":"11299_CR52","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.3892\/mmr.2015.3580","volume":"12","author":"H Jiang","year":"2015","unstructured":"Jiang, H. et al. Increased expression of neuropilin 1 is associated with epithelial ovarian carcinoma. Mol. Med. Rep. 12, 2114\u20132120 (2015).","journal-title":"Mol. Med. Rep."},{"key":"11299_CR53","first-page":"1031","volume":"328","author":"KN Sugahara","year":"2010","unstructured":"Sugahara, K. N. et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Sci. (1979). 328, 1031\u20131035 (2010).","journal-title":"Sci. (1979)"},{"key":"11299_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nano11123257","volume":"11","author":"L Sim\u00f3n-Gracia","year":"2021","unstructured":"Sim\u00f3n-Gracia, L. et al. Homing peptide-based targeting of tenascin-C and fibronectin in endometriosis. Nanomaterials 11, 1\u201328 (2021).","journal-title":"Nanomaterials"},{"key":"11299_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13550-024-01070-0","volume":"14","author":"B Trachsel","year":"2024","unstructured":"Trachsel, B. et al. Relaxed fibronectin: a potential novel target for imaging endometriotic lesions. EJNMMI Res. 14, 17 (2024).","journal-title":"EJNMMI Res."},{"key":"11299_CR56","doi-asserted-by":"crossref","unstructured":"Yeow, Y. L. et al. Immune-mediated ECM depletion improves tumour perfusion and payload delivery. EMBO Mol. Med 11, (2019).","DOI":"10.15252\/emmm.201910923"},{"key":"11299_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2018.01.029","volume":"274","author":"R Raav\u00e9","year":"2018","unstructured":"Raav\u00e9, R., van Kuppevelt, T. H. & Daamen, W. F. Chemotherapeutic drug delivery by tumoral extracellular matrix targeting. J. Control Release. 274, 1\u20138 (2018).","journal-title":"J. Control Release"},{"key":"11299_CR58","doi-asserted-by":"publisher","unstructured":"Maeda, H. Macromolecular therapeutics in cancer treatment: The EPR effect and beyond. J. Controlled Release  164, 138\u2013144.  https:\/\/doi.org\/10.1016\/j.jconrel.2012.04.038  (2012).","DOI":"10.1016\/j.jconrel.2012.04.038"},{"key":"11299_CR59","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-12-4561","volume":"73","author":"U Prabhakar","year":"2013","unstructured":"Prabhakar, U. et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73, 2412\u20132417 (2013).","journal-title":"Cancer Res."},{"key":"11299_CR60","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1021\/acs.bioconjchem.7b00304","volume":"28","author":"A Dal Corso","year":"2017","unstructured":"Dal Corso, A., Cazzamalli, S., G\u00e9bleux, R., Mattarella, M. & Neri, D. Protease-Cleavable linkers modulate the anticancer activity of noninternalizing Antibody-Drug conjugates. Bioconjug. Chem. 28, 1826\u20131833 (2017).","journal-title":"Bioconjug. Chem."},{"key":"11299_CR61","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1158\/1535-7163.MCT-15-0480","volume":"14","author":"R G\u00e9bleux","year":"2015","unstructured":"G\u00e9bleux, R., Wulhfard, S., Casi, G. & Neri, D. Antibody format and drug release rate determine the therapeutic activity of non-internalizing antibody-drug conjugates. Mol. Cancer Ther. 14, 2606 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"11299_CR62","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00432-013-1538-6","volume":"140","author":"R Locher","year":"2014","unstructured":"Locher, R. et al. Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of 131I-L19SIP in a prostate cancer patient. J. Cancer Res. Clin. Oncol. 140, 35\u201343 (2014).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"11299_CR63","first-page":"643","volume":"96","author":"D Male","year":"1987","unstructured":"Male, D., Champion, B. & Cooke, A. Adv. Immunol. Parasitol. 96, 643\u2013644 (1987).","journal-title":"Adv. Immunol. Parasitol."},{"key":"11299_CR64","doi-asserted-by":"publisher","first-page":"9381","DOI":"10.1073\/pnas.0403317101","volume":"101","author":"P Laakkonen","year":"2004","unstructured":"Laakkonen, P. et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc. Natl. Acad. Sci. U S A. 101, 9381\u20139386 (2004).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"11299_CR65","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/1535-7163.MCT-14-0366","volume":"14","author":"KN Sugahara","year":"2015","unstructured":"Sugahara, K. N. et al. Tumor-penetrating iRGD peptide inhibits metastasis. Mol. Cancer Ther. 14, 120\u2013128 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"11299_CR66","doi-asserted-by":"crossref","unstructured":"Maldonado, H. et al. Systemically administered wound-homing peptide accelerates wound healing by modulating syndecan-4 function. Nat. Commun. 14, 1456 (2023).","DOI":"10.1038\/s41467-023-43848-1"},{"key":"11299_CR67","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jconrel.2023.07.025","volume":"360","author":"J Puranen","year":"2023","unstructured":"Puranen, J. et al. Intravitreal CendR peptides target laser-induced choroidal neovascularization sites in mice. J. Controlled Release. 360, 810\u2013817 (2023).","journal-title":"J. Controlled Release"},{"key":"11299_CR68","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.biomaterials.2016.07.023","volume":"104","author":"L Sim\u00f3n-Gracia","year":"2016","unstructured":"Sim\u00f3n-Gracia, L. et al. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of Paclitaxel with polymersomes. Biomaterials 104, 247\u2013257 (2016).","journal-title":"Biomaterials"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11299-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11299-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11299-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:13:12Z","timestamp":1757376792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11299-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11299"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-11299-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5743295\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.T. and P.L. hold a patent on the PL2 peptide (\u201cBi-Specific Extracellular Matrix Binding Peptides and Methods of Use Thereof\u201d, WO. patent no. WO 2020\/161602 A1), and TT is an inventor of CendR peptides. Other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The fresh surgical ovarian carcinoma samples were obtained under protocols approved by the Ethics Committee of the University of Tartu, Estonia (permit #243\/T27). Additionally, informed consent was obtained from all the patients, and methods for using human samples were carried out under relevant guidelines and regulations accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and informed consent"}},{"value":"Animal experimentation procedures were approved by the Estonian Ministry of Agriculture, Committee of Animal Experimentation, projects #42 and #48 (IACUC). We confirm that all methods were performed in accordance with the relevant guidelines and regulations. We confirm that the study was conducted in accordance with the ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animals and ethics statement"}}],"article-number":"29369"}}